Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI: A Meta-Analysis

Mega, J.; Simon, T.; Collet, J.; L. Anderson, Jeffrey; Antman, E.; Bliden, K.; Cannon, C.; Danchin, N.; Giusti, B.; Gurbel, P.; Horne, B.; Hulot, J.; Kastrati, A.; Montalescot, G.; Neumann, F.; Shen, Lei-Bin; Sibbing, D.; Steg, P.; Trenk, D.; Wiviott, S.; Sabatine, M.

doi:10.1001/jama.2010.1543

Public

Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI: A Meta-Analysis

Shared by NobleBlocks on Oct 27, 2010 • 12:00 AM UTC

Authors:

J. Mega

T. Simon

J. Collet

Abstract

Content Clopidogrel, one of the most commonly prescribed medications, is a pro-drug requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on CYP2C19 genotype, but there is uncertainty regarding the clinical risk imparted by specific genotypes. Objective In patients t...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!